Novo Nordisk today announced the US launch of the Wegovy pill, the first oral GLP-1 option approved by the Food and Drug Administration (FDA) for chronic weight management. The introduction of an oral formulation marks a significant step forward in expanding patient choice and access to evidence-based obesity treatment.

The launch coincides with an expanded NovoCare experience, designed to help patients find trusted care, understand coverage options, and access ongoing support throughout their treatment journey. As part of this experience, patients seeking treatment with real FDA-approved products, now including the Wegovy pill, can connect with recognised care providers that offer comprehensive, longitudinal obesity care.

knownwell, a weight-inclusive primary care and metabolic health company offering both virtual and in-person care, is proud to be recognised as a NovoCare provider. Through this engagement, patients exploring the Wegovy pill can be connected to knownwell’s multi-disciplinary care model, which integrates medical, nutritional and behavioural support delivered through a national hybrid model.

“The availability of Wegovy pill represents an important evolution in obesity care—one that prioritises convenience, choice and meeting patients where they are. “We’re excited to be part of this new movement and to support patients who are seeking effective treatment options paired with high-quality and insurance-covered care,” said Brooke Boyarsky Pratt, CEO and Co-Founder, knownwell.

knownwell’s care is led by clinicians board-certified in obesity medicine and is designed to support patients beyond a prescription, with personalised treatment plans and ongoing engagement. The company offers both telehealth and in-person visits, enabling patients to choose how and where they receive care.

“The Wegovy pill expands what’s possible for patients who may prefer or benefit from an oral option. When innovative medications are paired with consistent clinical care, education, and support, patients are better positioned to achieve meaningful and sustainable health outcomes,” said Dr Angela Fitch, Chief Medical Officer and Co-Founder, knownwell.

The inclusion of knownwell on the NovoCare platform builds on the company’s ongoing efforts to collaborate with industry programmes that streamline access to independent, clinician-led metabolic care for patients across the US.